Application of tofacitinib citrate in the adjuvant treatment of senile degenerative heart valve disease

Abstract

The invention relates to novel application of a medicine, and in particular relates to an adjuvant treatment effect of tofacitinib on senile degenerative valvular disease. A clinical trial research shows that while conventional treatment is carried out on a patient with the senile degenerative valvular disease, the tofacitinib can be given for adjuvant treatment; the tofacitinib can be used for remarkably treating lung extravasated blood and pleural effusion symptoms of the patient with the senile degenerative valvular disease; various arrhythmia including auricular fibrillation and the like, atrial hypertrophy and ventricular hypertrophy are effectively relieved; the recurrence rate of the disease can be reduced, and the life quality of the patient is improved.

Description

technical field

[0001] The present invention relates to a new application of medicine, in particular to the application of tofacitinib citrate in adjuvant treatment medicine for senile degenerative heart valve disease. Background technique

[0002] Senile degenerative heart valvular disease (SDHVD) is also known as senile calcific heart valve disease and senile heart calcification syndrome. The disease refers to the degeneration, fibrosis, thickening and calcification of the connective tissue of the heart valve on the basis of the original normal valve or mild valve abnormality, which causes the function of the valve and the stent. Abnormalities, mainly invading the aortic valve and mitral valve ring, mainly including calcified aortic valve stenosis and regurgitation, mitral valve ring and mitral valve calcification, and combined valve calcification with two valves at the same time, etc. In severe cases, it causes hemodynamic changes, which has become one of the main causes...

Examples

Embodiment 1

[0011] Example 1 Adjuvant therapeutic effect of tofacitinib citrate on elderly patients with degenerative heart valve disease

[0012] 1. Materials and methods

[0013] 1.1 Experimental objects and grouping

[0014] 69 cases of SDHVD patients (diagnostic criteria: thickening of aortic valve and mitral valve or valve ring, calcification, enhanced reflection, regular edge, decreased activity; X-ray examination found that the aortic valve or mitral valve had calcification ; A systolic murmur above grade two or a diastolic murmur was heard in the aortic valve area, or murmurs were heard in both the aortic valve area and the mitral valve area.) Randomly divided into observation group 39 cases and control group 30 cases, two There was no significant difference in the gender and condition of the two groups after statistical processing ( p >0.05), it is comparable.

[0015] 1.2 Treatment methods

[0016] Patients in the observation group and the control group were actively treated...

technical field

[0001] The present invention relates to a new application of medicine, in particular to the application of tofacitinib citrate in adjuvant treatment medicine for senile degenerative heart valve disease. Background technique

[0002] Senile degenerative heart valvular disease (SDHVD) is also known as senile calcific heart valve disease and senile heart calcification syndrome. The disease refers to the degeneration, fibrosis, thickening and calcification of the connective tissue of the heart valve on the basis of the original normal valve or mild valve abnormality, which causes the function of the valve and the stent. Abnormalities, mainly invading the aortic valve and mitral valve ring, mainly including calcified aortic valve stenosis and regurgitation, mitral valve ring and mitral valve calcification, and combined valve calcification with two valves at the same time, etc. In severe cases, it causes hemodynamic changes, which has become one of the main causes...

Examples

Embodiment 1

[0011] Example 1 Adjuvant therapeutic effect of tofacitinib citrate on elderly patients with degenerative heart valve disease

[0012] 1. Materials and methods

[0013] 1.1 Experimental objects and grouping

[0014] 69 cases of SDHVD patients (diagnostic criteria: thickening of aortic valve and mitral valve or valve ring, calcification, enhanced reflection, regular edge, decreased activity; X-ray examination found that the aortic valve or mitral valve had calcification ; A systolic murmur above grade two or a diastolic murmur was heard in the aortic valve area, or murmurs were heard in both the aortic valve area and the mitral valve area.) Randomly divided into observation group 39 cases and control group 30 cases, two There was no significant difference in the gender and condition of the two groups after statistical processing ( p >0.05), it is comparable.

[0015] 1.2 Treatment methods

[0016] Patients in the observation group and the control group were actively treated...